Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis

NCT00544037 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00544037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00544037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
September 30, 2007
Completion date
January 31, 2011
Enrollment
283 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis